Loss of CITED2 has been implicated in restored sensitivity to platinum compounds in resistant ovarian cancer cells (Yanagie et al, 2009) and in increased invasiveness in a colon cancer model (Bai and Merchant, 2007). Here, CITED2 is linked to malignant colon neoplasm.